[Special Stock] Pharmaresearch, the Originator of the Skin Booster Market... "At the Steep Growth Starting Point"

Pharmaresearch is showing strong performance. It appears that securities firms' analysis, which expects rapid growth of the skin booster Rejuran, has had an impact.

As of 9:59 AM on the 10th, Pharmaresearch was trading at 195,300 KRW, up 12,500 KRW (6.84%) compared to the previous trading day.

Junghyun Kim, a researcher at KB Securities, said, "The main investment point of Pharmaresearch is the skin booster Rejuran," adding, "Many investors already understand well Rejuran's collagen regeneration effect and high commercial viability, and the sales of the medical device division (including Conjuran), which includes this product, are expected to grow from 136.1 billion KRW last year to 175.5 billion KRW this year."

He emphasized, "In a rapidly growing skin booster market, Rejuran's growth potential is limitless," and added, "With a recent large-scale investment of 200 billion KRW from CVC, we can also expect regional expansion into Europe and securing new growth engines."

This content was produced with the assistance of AI translation services.